Daratumumab (CAS 945721-28-8) is a human IgG1 monoclonal antibody that targets CD38, a cell surface protein overexpressed in multiple myeloma cells. By binding to CD38, daratumumab induces tumor cell death through mechanisms such as antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
Key Features:Target Specificity: Binds to CD38, a protein overexpressed in multiple myeloma cells.
- Mechanism of Action: Induces tumor cell death via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
- Molecular Characteristics: Human IgG1 monoclonal antibody.
Applications:
- Multiple Myeloma Treatment: Used alone or in combination with other therapies for treating multiple myeloma.
- Research: Utilized in laboratory settings to study CD38’s role in various diseases.
Daratumumab is administered intravenously and is typically used in combination with other medications to enhance its efficacy. Common side effects include fatigue, nausea, and low blood counts. It is important to monitor patients for potential infusion-related reactions during administration.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
